Aarey Drugs & Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Aarey Drugs & Pharmaceuticals's earnings have been declining at an average annual rate of -12.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 5.4% per year. Aarey Drugs & Pharmaceuticals's return on equity is 2.4%, and it has net margins of 0.8%.
Key information
-12.1%
Earnings growth rate
-13.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.4% |
| Return on equity | 2.4% |
| Net Margin | 0.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aarey Drugs & Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,481 | 29 | 19 | 0 |
| 30 Sep 23 | 3,343 | 24 | 19 | 0 |
| 30 Jun 23 | 3,509 | 37 | 20 | 0 |
| 31 Mar 23 | 4,190 | 38 | 16 | 0 |
| 31 Dec 22 | 3,768 | 27 | -10 | 0 |
| 30 Sep 22 | 4,542 | 41 | 3 | 0 |
| 30 Jun 22 | 5,169 | 48 | 49 | 0 |
| 31 Mar 22 | 4,929 | 66 | 20 | 0 |
| 31 Dec 21 | 5,537 | 87 | 13 | 0 |
| 30 Sep 21 | 5,068 | 85 | 19 | 0 |
| 30 Jun 21 | 4,277 | 77 | 13 | 0 |
| 31 Mar 21 | 3,514 | 65 | 4 | 0 |
| 31 Dec 20 | 2,838 | 61 | 1 | 0 |
| 30 Sep 20 | 2,462 | 58 | 55 | 0 |
| 30 Jun 20 | 2,591 | 51 | 57 | 0 |
| 31 Mar 20 | 3,009 | 58 | 4 | 0 |
| 31 Dec 19 | 3,282 | 55 | 20 | 0 |
| 30 Sep 19 | 3,470 | 57 | 15 | 0 |
| 30 Jun 19 | 3,536 | 65 | 73 | 0 |
| 31 Mar 19 | 3,562 | 65 | 13 | 0 |
| 31 Dec 18 | 3,343 | 66 | 16 | 0 |
| 30 Sep 18 | 3,454 | 69 | 12 | 0 |
| 30 Jun 18 | 3,429 | 64 | 2 | 0 |
| 31 Mar 18 | 3,493 | 62 | 7 | 0 |
| 31 Dec 17 | 3,554 | 67 | 8 | 0 |
| 30 Sep 17 | 3,619 | 67 | 6 | 0 |
| 30 Jun 17 | 3,751 | 67 | 38 | 0 |
| 31 Mar 17 | 3,960 | 55 | 6 | 0 |
| 31 Dec 16 | 3,817 | 46 | 7 | 0 |
| 30 Sep 16 | 3,490 | 30 | 7 | 0 |
| 30 Jun 16 | 2,988 | 18 | 23 | 0 |
| 31 Mar 16 | 2,460 | 13 | 3 | 0 |
| 31 Dec 15 | 2,146 | 13 | 17 | 0 |
| 30 Sep 15 | 2,040 | 13 | 15 | 0 |
| 30 Jun 15 | 2,207 | 11 | 35 | 0 |
| 31 Mar 15 | 2,134 | 11 | 3 | 0 |
| 31 Dec 14 | 1,732 | 8 | 10 | 0 |
| 30 Sep 14 | 1,788 | 9 | 15 | 0 |
| 30 Jun 14 | 1,874 | 14 | 45 | 0 |
| 31 Mar 14 | 1,997 | 11 | 19 | 0 |
| 31 Dec 13 | 2,118 | 8 | 21 | 0 |
| 30 Sep 13 | 2,017 | 8 | 23 | 0 |
| 30 Jun 13 | 1,847 | 5 | 26 | 0 |
Quality Earnings: 524412 has high quality earnings.
Growing Profit Margin: 524412's current net profit margins (0.8%) are higher than last year (0.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524412's earnings have declined by 12.1% per year over the past 5 years.
Accelerating Growth: 524412's earnings growth over the past year (8.7%) exceeds its 5-year average (-12.1% per year).
Earnings vs Industry: 524412 earnings growth over the past year (8.7%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 524412's Return on Equity (2.4%) is considered low.